Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.64
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp....
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Data is available to registered users only
Buy
Sell